Overview

Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety

Status:
Recruiting
Trial end date:
2024-09-15
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the tolerability of the new formulation of Dorzolamide+Timolol preservative free developed in OSD Aptar Pharma multidose system in comparison with Dorzolamide +Timolol BAK preserved ophthalmic formulation.
Phase:
Phase 4
Details
Lead Sponsor:
Laboratorios Poen
Treatments:
Dorzolamide
Ophthalmic Solutions
Timolol